Pemgarda Maintains Effectiveness Against Evolving SARS-CoV-2 Variants
Invivyd announced that new in vitro data confirms Pemgarda (pemivibart) continues to effectively neutralize the dominant SARS-CoV-2 variant XEC. This underscores the monoclonal antibody's ongoing effectiveness despite the virus’s evolving variants. The …